News Article | December 2, 2016
On Dec. 2, 2016, CURE® magazine will host the 4th Annual MPN Heroes® Recognition Event at the Hard Rock Hotel San Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field of rare blood cancers known as myeloproliferative neoplasms (MPNs) by going above and beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment to individual patients. This year’s event, being held prior to the 58th American Society of Hematology Annual Meeting, will recognize Ross Levine, MD; Elliott Winton, MD; Erin Blackwell, RN, BSN, OCN; Bonnie Blankert; David Wallace; Ann Brazeau; Andrew Schorr; and Patricia Koenig. Joining the honorees as keynote speaker is cancer researcher and Pulitzer Prize-winning writer Siddhartha Mukherjee, MD, PhD. “We celebrate these real-life heroes who work every day helping patients and families. Honoring these outstanding caregivers and advocates reflects our dedication to the cancer community,” said CURE Media Group President Michael J. Hennessy, Jr. The MPN Heroes® Recognition Event is made possible with support from Incyte Corporation, CancerCare, Cancer Support Community, the Leukemia & Lymphoma Society, MPN Advocacy & Education International, the MPN Education Foundation, the MPN Research Foundation and the National Organization for Rare Disorders. A steering committee of patients, advocates and health care professionals selected honorees from among the scores of people and groups nominated by the MPN community. This year’s award recipients include two physicians, a nurse, a caregiver and four patient advocates. Of these, four awards are going to individuals in the category “Commitment to the Individual”: The second category of recipients includes individuals whose continuous efforts have had a significant impact on the broader MPN community: In an effort to honor the four Heroes recognized for their impact on the broader MPN community and further increase awareness, Incyte will make a $25,000 charitable donation per recipient to an organization engaged in MPN activities. Keynote speaker Siddhartha Mukherjee, MD, PhD, will join the hundreds of guests honoring the 2016 MPN Heroes® and share new insights into the causes and cures of cancer. A graduate of Stanford University, Harvard Medical School and Oxford University, Dr. Mukherjee is a cancer specialist whose laboratory is at the forefront of discovering new cancer drugs using innovative biological methods. In his Pulitzer Prize-winning book, The Emperor of All Maladies: A Biography of Cancer, Dr. Mukherjee explores the origins and causes of cancer, its deadly effect on the human body, how it has virtually enveloped modern civilization, and the epic battles that are taking place to control, cure, and conquer it. “Incyte Corporation is pleased to once again partner with CURE® magazine to sponsor the MPN Heroes Program,” said Hervé Hoppenot, CEO of Incyte. “Our goal with this program is to create as many opportunities as possible for people with MPNs to continually be heard and supported.” Visit http://www.MPNHeroes.com to learn more about this year’s MPN Heroes®, the 2016 Recognition Program Rules and Steering Committee members. Individuals or entities supported through funding or directed by Incyte are not eligible for consideration or recognition. Supporting the recognition of MPN Heroes® and the MPN community is an ongoing effort of Incyte’s Voices of MPN awareness program. For every post made on The Wall of Voices, Incyte will donate $5 to the MPN Research Foundation. For more information, visit http://www.voicesofmpn.com. About CURE Media Group CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry leading website, CUREtoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Plainsboro, N.J.-based Michael J. Hennessy Associates, Inc. family of businesses, which includes the acclaimed OncLive® (http://www.onclive.com) platform of resources for the practicing oncologist. For more information, visit http://www.curetoday.com or http://www.mjhassoc.com/. About Incyte Incyte Corporation is a Wilmington, Del. -based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the company’s website at http://www.incyte.com.
News Article | November 8, 2016
Once again, Cruise Planners agents have exceeded their business growth from last year, which was announced at the “I Am CP” Convention. The travel franchise company, which is an American Express Travel Representative and the nation’s largest home-based travel agent franchise network, hosted 600 travel franchise owners at its sold-out annual convention in Miami. At the convention, hosted at the InterContinental Miami Hotel, the company launched new travel agent booking tools, enhanced its automatic and strategic marketing programs and increased its focus on both land and luxury travel. Cruise Planners executives and co-owners kick off the travel company’s annual Convention in Miami. The I Am CP themed event showcased the highlights from 2016 and revealed the most technology tools the company has ever launched at Convention. “Our goal is to ensure that Cruise Planners agents are the most successful travel agents in the industry – for both land and cruise travel,” says Michelle Fee, CEO and co-founder of Cruise Planners, an American Express Travel Representative. “We create the best tools in the industry in order for agents to be the go-to experts as they hone their individual talents and strengthen relationships with customers and suppliers and this year, our agents went wild for our technology and marketing announcements.” Cruise Planners is always introducing new tools to create automatic and strategic marketing programs so agents can focus on selling travel. Below are the most popular and innovative: “All of these tools and announcements are designed with the travel agent in mind,” Fee said. “We specifically create innovative technology and marketing programs to enhance travel agents’ individual businesses. We want them to stay competitive, while focusing on travel and still being involved in their communities.” As always, Cruise Planners incorporated charitable giving with the 600+ group walking in the Leukemia & Lymphoma Society’s Light the Night at Bayfront Park in Miami. As the convention concludes, hundreds of agents will sail on Royal Caribbean International’s inaugural North American voyage of Harmony of the Seas, out of Port Everglades. “I am motivated by our entire network of travel professionals and each year, our convention invigorates agents and helps set the tone for the upcoming year,” Fee said. “Our sales for the upcoming few years are trending higher than ever and we anticipate these new tools will help positively impact that even more.” About Cruise Planners, an American Express Travel Representative Cruise Planners, an American Express Travel Representative, is the nation’s largest home-based travel agent franchise network in the travel industry. Cruise Planners operates a network of more than 1,500 franchise owners who independently book amazing vacation and travel experiences for their clients. The Florida-based Home Office Team positions a nation-wide network of franchise owners for success by providing innovative marketing, booking and technology tools, as well as professional development and hands-on training with the industry’s top executives. The company continues to be lauded and has been named the No.1 travel franchise by Entrepreneur magazine for 13 consecutive years. Cruise Planners was recently featured in Entrepreneur as one of the top 30 franchise innovators in technology, has been consistently named as one of the Top Women-Owned Businesses by the South Florida Business Journal, is on the Inc. 5000 list as one of the fastest-growing private companies in America, has been ranked as the #1 travel franchise by Franchise Business Review for 5 years in a row, and was recognized as one of the Top Workplaces by the Sun Sentinel since it started ranking companies. Headquartered in Coral Springs, Fla. with more than 22 years of experience, Cruise Planners has achieved top producer status with every major cruise line. Accolades include numerous Magellan Awards from Travel Weekly for the past seven years, American Express Travel Representative Excellence Award for 11 consecutive years (2004-2014), American Express Agency of the Year (2010), Royal Caribbean International Chairman’s Award (2015), Royal Caribbean International President’s Award for Overall Achievement (2012 and 2014), Royal Caribbean International Home-Based Partner of the Year (2007-2013), Norwegian Cruise Line Franchise Agency of the Year (2011-2015), Celebrity Cruises Field Sales Account of the Year (2015), Celebrity Cruises Home-Based Account of the Year (2013-2014) and Celebrity Cruises Southeast Region Travel Agent Partner of the Year (2010), American Express Vacations Best of the Best Globe Award (2008-2015), Globus Family of Brands Premier Agency Partner (2009-2014), Platinum Member of the 500 Club for Sales Excellence (2014), Platinum Circle Member with Viking River Cruises (2009-2012), Uniworld Boutique River Cruise Collection Top Producer (2008-2014) and Regent Seven Seas Cruises Top Producer. Cruise Planners is one of the Top 50 franchises for Veterans according to GI magazine, the Top Franchise Brand for Veterans according to Franchise Business Review, has been named one of the Top 25 franchises for African-Americans by Black Enterprise magazine and is a member of the International Gay & Lesbian Travel Association. For more information, visit http://www.cruiseplanners.com.
News Article | February 28, 2017
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite Pharma, Inc., (Nasdaq:KITE) today announced positive data from the primary analysis of ZUMA-1 for its lead CAR-T candidate, axicabtagene ciloleucel (previously referred to as KTE-C19), in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma (NHL). The study met the primary endpoint of objective response rate (ORR), or rates of tumor response (complete response + partial response) recorded after a single infusion of axicabtagene ciloleucel, with 82 percent (p<0.0001). These results demonstrate the treatment effect of axicabtagene ciloleucel in a patient population with multiple types of aggressive NHL, including diffuse large B-cell lymphoma (DLBCL) enrolled in Cohort 1, as well as primary mediastinal B-cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL) enrolled in Cohort 2. One hundred one patients were treated in ZUMA-1. The following table shows the ORR and rate of complete response (CR) as well as the month 6 ORR and CR: Four of the 101 patients in ongoing CR did not have a month 6 tumor assessment prior to the data cut-off and are therefore categorized as non-responders for month 6 in the table above. These patients have an opportunity to be counted as a month 6 CR in a follow-up analysis, which may increase the month 6 response and month 6 CR rate. At month 6, 41 percent of treated patients achieved a response, including 36 percent in CR. Five of the 101 patients (5 percent) continue to experience highly significant and durable partial responses (PR) with minimal abnormalities in PET scans. One of these PRs converted to a CR at month 9. With a median follow-up of 8.7 months for this primary analysis, the median overall survival (OS) has not yet been reached. In a similar patient population, the median OS was estimated to be 6.6 months (SCHOLAR-1 study, ASCO 2016). The most common grade 3 or higher adverse events included anemia (43 percent), neutropenia (39 percent), decreased neutrophil count (32 percent), febrile neutropenia (31 percent), decreased white blood cell count (29 percent), thrombocytopenia (24 percent), encephalopathy (21 percent) and decreased lymphocyte count (20 percent). As compared to the interim analysis, grade 3 or higher cytokine release syndrome (CRS) decreased from 18 percent to 13 percent and neurologic events decreased from 34 percent to 28 percent. There were no cases of cerebral edema. As previously reported at the American Society of Hematology Annual Meeting in 2016, there were three deaths not due to disease progression in the study. Two events, one hemophagocytic lymphohistiocytosis and one cardiac arrest in the setting of CRS, were deemed related to axicabtagene ciloleucel. The third case, a pulmonary embolism, was deemed unrelated. Between the interim analysis that included 62 patients, and this primary analysis which now includes all 101 patients, there were no additional deaths due to adverse events. “These results with axicabtagene ciloleucel are exceptional and suggest that more than a third of patients with refractory aggressive NHL could potentially be cured after a single infusion of axicabtagene ciloleucel,” said Jeff Wiezorek, M.D., Senior Vice President of Clinical Development. “The ZUMA-1 study was built on a foundation of support and commitment from Dr. Steven Rosenberg and the National Cancer Institute and our ZUMA-1 clinical trial investigators who believed in the potential for CAR-T therapy to change the paradigm of cancer treatment.” Kite intends to seek regulatory approval of axicabtagene ciloleucel in aggressive NHL based upon the combined data from all 101 patients and plans to complete its rolling submission of the Biologics License Application (BLA) by the end of the first quarter of 2017. In addition, Kite plans to submit a marketing authorization application (MAA) for axicabtagene ciloleucel for the treatment of relapsed or refractory DLBCL, PMBCL and TFL with the European Medicines Agency (EMA) in 2017. “We know as clinicians that patients with aggressive lymphoma who do not respond to their previous treatments have a very poor prognosis. In fact, we know from the SCHOLAR-1 study, these patients have only an eight percent chance of achieving a complete response with current therapies,” said Frederick L. Locke, M.D., ZUMA-1 Co-Lead Investigator, and Director of Research for the Immune Cell Therapy Program at Moffitt Cancer Center in Tampa, Florida. “Several patients we treated at Moffitt Cancer Center experienced a rapid and durable complete response with this first-of-its kind therapy. The ZUMA-1 study results suggest that axicabtagene ciloleucel could become a new standard of care for patients with refractory aggressive lymphoma.” Sattva S. Neelapu, M.D., Department of Lymphoma/Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, served as a co-lead investigator in the ZUMA-1 trial. Full data from the primary analysis will be presented at the American Association for Cancer Research in April 2017 in Washington, D.C. ZUMA-1 is supported in part by funding from The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program®. Conference Call and Webcast Details Kite will host a live conference call and webcast today at 9:00 AM Eastern Time (6:00 AM Pacific Time) to discuss the results of this primary analysis. To access the live conference call by telephone, please dial (888) 771-4371 (U.S.) or (847) 585-4405 (International). The conference ID number for the live call is 44040763. The webcast will be made available on the Company's website at www.kitepharma.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days. About axicabtagene ciloleucel Kite Pharma's lead product candidate, axicabtagene ciloleucel, is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. Axicabtagene ciloleucel has been granted Breakthrough Therapy Designation status for diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) regulatory support for DLBCL in the EU. About Kite Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability of completing a BLA submission with the FDA, completing an MAA with the EMA, obtaining regulatory approval and commercially launching axicabtagene ciloleucel. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended September 30, 2016. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Leukemia & Lymphoma Society | Date: 2013-03-08
A method is provided to associate an independent entity that collects financial instruments on behalf of an organization with funds collected on behalf of the organization. A system is also provided for associating an independent entity that collects financial instruments on behalf of an organization with funds collected on behalf of the organization. An apparatus may also be provided for associating an independent entity that collects financial instruments on behalf of an organization with funds collected on behalf of the organization.
News Article | March 1, 2017
Global Traveler’s annual online charity travel auction launches today, and runs through May 1. For the seventh consecutive year, 100 percent of the proceeds benefit The Leukemia & Lymphoma Society. Log on to global17.auction-bid.org, and bid on a number of travel items, including business-class airline tickets, 5-star hotel stays and travel products. Prizes include round-trip, business-class tickets on China Eastern Airlines, China Airlines and Singapore Airlines. Hotel stays are available at Paradisus Cancun, InterContinental Los Angeles, The Westin Dubai, Montage Beverly Hills, The Breakers Palm Beach, The Phoenician, The Time Nyack, Mandarin Orchard Singapore and many more. Additional items up for grabs this year are a Gevril watch, Bose SoundLink wireless headphones and Delsey luggage. The Leukemia & Lymphoma Society (lls.org) is dedicated to finding a cure for blood and lymph cancers. LLS awarded more than $750 million in research funding for all blood cancers. For more information about Global Traveler, visit globaltravelerusa.com. Bidding ends May 1 at global17.auction-bid.org. About Global Traveler Global Traveler, the only AAM-audited U.S.-based magazine for the international business traveler, is a business travel and lifestyle publication with an AAM-audited paid circulation of 112,000+. About FXEXpress Publications, Inc. FXExpress Publications, Inc., based in Yardley, Pa., is a privately held company publishing Global Traveler, eFlyer USA, eFlyer Asia, Trazee Travel and several annuals; and also operating globaltravelerusa.com, globaltravelerusa.com/blog and trazeetravel.com.
News Article | February 28, 2017
NEWARK, N.J.--(BUSINESS WIRE)--Three organizations, including two nonprofits, have recently hired Prudential Retirement to administer their defined contribution plans, the company announced today. Prudential Retirement, among the industry’s largest recordkeepers, is a business unit of Prudential Financial, Inc. (NYSE:PRU). “In a market that is becoming increasingly competitive, these latest client wins demonstrate the continued demand for retirement plan providers that invest in technologies and enhancements that increase participant engagement,” said Harry Dalessio, senior vice president and head of Sales & Strategic Relationships. “We’re pleased to partner with each of these clients to support their efforts to improve their employees’ retirement outcomes.” Prudential Retirement will oversee a total of $132 million in defined contribution assets across the three plans. The three new clients include: “We’re passionate about the work we do each day to cure leukemia and improve the quality of life of patients and their families,” said JR Miller, senior vice president, finance at Leukemia & Lymphoma Society. “We are also passionate about ensuring our employees can come to work every day and know that we are also invested in helping them achieve financial security through a workplace retirement plan.” “With their 90 years’ experience and wealth of on-line tools, Prudential was selected to help Keystone recruit and retain employees and to assist our employees in achieving their retirement goals,” said Jennifer Allison, vice president of Human Resources for Keystone Human Services. “We were impressed by Prudential because it was clear that they had done their homework. They understand our industry and have client experience working with law firms to help them better prepare their employees for retirement,” said Marc Merklin, managing partner at Brouse McDowell. Prudential Retirement delivers retirement plan solutions for public, private, and nonprofit organizations. Services include defined contribution, defined benefit and non-qualified deferred compensation recordkeeping, administrative services, investment management, comprehensive employee education and communications, and trustee services, as well as a variety of products and strategies, including institutional investment and income products, pension risk transfer solutions and structured settlement services. With more than 85 years of retirement experience, Prudential Retirement helps meet the needs of 4.2 million participants and annuitants. Prudential Retirement has $386.2 billion in retirement account values as of Dec. 31, 2016. Retirement products and services are provided by Prudential Retirement Insurance and Annuity Company (PRIAC), Hartford, Conn., or its affiliates. About Prudential Financial, Inc. Prudential Financial, Inc. (NYSE: PRU), a financial services leader, has operations in the United States, Asia, Europe and Latin America. Prudential’s diverse and talented employees are committed to helping individual and institutional customers grow and protect their wealth through a variety of products and services, including life insurance, annuities, retirement-related services, mutual funds and investment management. In the U.S., Prudential’s iconic Rock symbol has stood for strength, stability, expertise and innovation for more than a century. For more information, please visit http://www.news.prudential.com/.
News Article | November 16, 2016
RYE BROOK, N.Y., Nov. 16, 2016 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world,...
News Article | February 15, 2017
Rand Internet Marketing, a professional website design, web development, and internet marketing company based out of Fort Lauderdale, Florida, has partnered up with Shuup, a multi-vendor, frontend B2B eCommerce platform. Rand is excited to announce one of their newest partnerships with Shuup. The open-source eCommerce platform supplies its users with efficient and effective custom features which allow for the ultimate tailored user experience. Clients can now have total and complete control over every aspect of their online store. Shuup’s strategies complement Rand’s dedication to enhance eCommerce retailers and the company is excited for a prosperous year ahead using this adaptable platform. "At Rand Marketing, we know that building an E-commerce site with an advanced shopping cart platform like Shuup is the cornerstone of selling online. However, it's just as crucial for merchants to establish a marketing plan, identifying how they will attract targeted shoppers to their new digital store, and how they will keep shoppers engaged so that they continue to return and make future purchases. We're proud to be partnering with Shuup to help bring together their modern and robust E-commerce system, with our agencies experience and resources, in order to help online stores grow and thrive by engaging in digital marketing campaigns such as Search Engine Optimization, Pay Per Click Marketing, Social Media Marketing, and E-mail Marketing,” said Robert Rand, Chief Technology Officer at Rand Internet Marketing. Many online retailers have converted to Shuup for its speed, ease of use, adaptability, and full fleet of outstanding features. Shuup boats superior performance, advanced features, and a tailored approach in an effort to boost sales and ultimately ROI. Shuup gives users a whole new eCommerce experience, one that is simplified, intuitive, and user friendly. “Shuup is on its way to becoming the number one eCommerce platform by redefining the entire concept and business model in a similar way to how digital photography redefined the camera industry. We will open the doors not just for the big players in the industry, but to everyone who has a dream to become an online merchant. Partnering with Rand Internet Marketing brings value added services to both of our companies’ business clients”,” said Tomi Alapaattikoski, CEO of Shuup. Rand Internet Marketing, named to the 2016 Inc 5000 list, provides professional website design, development, and programming in addition to online marketing services to hundreds of national and South Florida-based businesses. Led by founder and CEO, Seth Rand who was a 2016 South Florida Business Journal 40 Under 40 Honoree, the Fort Lauderdale-based firm has grown since its inception in 2010 to more than 20 in-house designers, developers, and internet marketers. The Rand team specializes in responsive website design and programming, including WordPress, Magento, WooCommerce, Shopify, Zoey, 3dcart and other e-commerce platforms; SEO (search engine optimization) and Google AdWords PPC (pay-per-click) campaigns; social media marketing; and online content marketing. Rand Internet Marketing was named a Premier Google Partner in 2016, a Google Partner AllStar in 2015 and also holds an A+ rating with the Better Business Bureau. The Rand team also supports the community through its support of local non-profit organizations such as the Leukemia & Lymphoma Society, Autism Speaks, Abi's Place, The Multiple Sclerosis Foundation and more. Shuup is an open source enterprise eCommerce solution for customized B2B and B2C ecommerce stores and other complex, business critical operations. It is built to get merchants’ products everywhere consumers are: search engines, sales channels, comparison shopping engines, social media, Android and iOS apps, blogs, and more. Shuup streamlines how you manage your online business or marketplace. As a web consulting firm, Shuup’s programmers created hundreds of eCommerce projects with platforms such as Magento, which became dramatically less scalable with increased customization. The idea was born to create a platform in which scalability is not in correlation with a project’s complexity and that is lean, fast to run, and open source. As an open source project, Shuup is publicly available to anyone who desires to sell goods and services online. Removing high license fees allows enterprises to create projects for next to nothing, with lifelong free updates and feature additions, increasing ROI over other enterprise platforms. Shuup has attract a lot of global interest and received multiple awards including Red Herring Top 100 Europe award and a position on the Deloitte Technology Fast 50 Finland list. For more information, call (888) 902-6337 or contact us at firstname.lastname@example.org or https://www.shuup.com/en/contact-us/.
News Article | February 22, 2017
DEERFIELD, Ill.--(BUSINESS WIRE)--Furthering its commitment to personalized patient care and continuing education for its pharmacy staff, Walgreens has designated more than 50 of its local specialty pharmacies as cancer-specialized locations led by pharmacists and pharmacy technicians who have advanced cancer training and expertise and are committed to making sure patients get the medications and answers they need when they need them. The pharmacy staff at these locations have completed a cancer-focused curriculum of advanced education courses, focused on colorectal, lung, prostate and breast cancer, as well as various blood cancers such as leukemia, lymphomas, multiple myeloma, myeloproliferative neoplasms and myelodysplatic syndrome. “We are continually looking for ways to better support and educate our cancer patients on their medication regimens, while helping to improve their quality of care,” said Matthew Farber, Walgreens senior director for oncology disease state management. “With the continued advances in new oral therapies for cancer care, our pharmacists at these specialty locations are playing an integral role in working with patients’ physicians, nurses, social workers and financial counselors.” Walgreens cancer-specialized pharmacies help patients access, afford and stay on their medication while also helping to successfully transition them into survivorship care. Walgreens pharmacists and technicians collaborate with other providers to help manage any medication side effects, and can assist in finding financial assistance options, if necessary. The Leukemia & Lymphoma Society (LLS), the world’s largest voluntary health agency dedicated to blood cancers, along with input from blood cancer experts from academia, developed clinical training courses, resources and certification for Walgreens specialty pharmacists and technicians to learn about and implement the latest evidence-based standards and guidelines for blood cancer care. LLS will be awarding blood cancer certifications to all of the Walgreens cancer-specialized pharmacies upon completion of their blood cancer courses. The education-focused initiative is part of an ongoing collaboration between Walgreens and LLS. One of its objectives has been to implement an education and training program to help enhance pharmacists’ knowledge of blood cancers and treatments, as part of the overall cancer care continuum. “We are passionate about understanding, meeting and exceeding the needs of blood cancer patients,” said Louis J. DeGennaro, Ph.D., LLS president and CEO. “Our programs, priorities and policies are driven by what is right for patients. In collaboration with Walgreens, we are making an impact on the health care of the more than 1.2 million people in the U.S. living with or in remission from a blood cancer.” Walgreens pharmacy staff at these specialized locations have also completed the following training: The company will continue to offer additional education courses from some of the aforementioned organizations, as well as other cancer experts and educators, including the National Association of Specialty Pharmacy (NASP) and ProCE Inc., a continuing pharmacy and medical education company. Walgreens has designed its oncology clinical programs to engage the patient and work together to help overcome medication adherence barriers throughout their treatment. The team of clinically-trained oncology pharmacy staff collaborates with patients’ health care teams to bridge the clinical and communication gaps that can arise within the patient population. “It is increasingly the case that a pharmacist, either over the phone, in person or via a mobile or web chat, will have the last conversation with a patient prior to the initiation of their oral therapies,” added Farber. “This offers a tremendous opportunity for our cancer-specialized pharmacies to help ensure the success of a patient’s treatment regimen.” Walgreens (www.walgreens.com), one of the nation's largest drugstore chains, is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the first global pharmacy-led, health and wellbeing enterprise. More than 10 million customers interact with Walgreens each day in communities across America, using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice. Walgreens operates 8,175 drugstores with a presence in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands. Walgreens omnichannel business includes Walgreens.com and VisionDirect.com. Approximately 400 Walgreens stores offer Healthcare Clinic or other provider retail clinic services.
News Article | February 15, 2017
Rand Internet Marketing, a professional website design, web development, and internet marketing company based out of South Florida, has partnered up with Apruve to bring its leading B2B e-Commerce Credit Solution to Rand Marketing’s roster of clientele. Rand Internet Marketing is known throughout South Florida and on a national level as one of the leading providers of enhanced services and solutions for its wide client base. The company offers a variety of internet marketing services such as search engine optimization (SEO), pay-per-click (PPC), responsive website design and development on a selection of e-Commerce platforms, logo and graphic design, social media setup and marketing, online banner advertising, online content marketing, among many more. Apruve is a B2B credit management platform streamlining the process of extending credit to businesses. Buyers can be approved for a credit limit in just 60 seconds and manage their purchases through an online portal. Sellers are paid within 24 hours of a purchase where they no longer worry about collecting payments, sending invoices or tracking down default payments. Extending credit is now frictionless, quick and risk-free. "At Rand Marketing, we've been helping B2B businesses, including Brands, Manufacturers, Wholesalers, and Distributors to sell products via the internet for many years. Assisting those organizations to properly offer Net Terms has always been a challenge. We're excited to now have a stronger offering to bring to our clients, allowing B2B shoppers to apply for a line of credit, and utilize only their remaining available credit in the E-commerce checkout process. It's light years ahead of manually reviewing applications for credit terms, and then taking unlimited orders from approved clients, having to manual reconcile orders after-the-fact to make sure that customers have enough credit available for their purchases. By streamlining the process, we're helping B2B merchants to cut down on manual labor and human error. Even better, merchants get paid quicker, and Apruve takes on the risk of buyers defaulting on payments - including for offline orders, such as phone orders,” said Robert Rand, Chief Technical Officer at Rand Internet Marketing. “Both Apruve and Rand have proven track records with their clients. It was an obvious opportunity to team up with a creative marketing firm whose focus revolves around e-Commerce sites. Our Credit Management platform goes hand-in-hand with the sites they build for clients; they already had a full-service solution, but with Apruve they can give their customers a payment gateway that streamlines the entire buying process,” stated Michael Noble, CEO at Apruve. Rand Internet Marketing, named to the 2016 Inc 5000 list, provides professional website design, development, and programming in addition to online marketing services to hundreds of national and South Florida-based businesses. Led by founder and CEO, Seth Rand who was a 2016 South Florida Business Journal 40 Under 40 Honoree, the Fort Lauderdale-based firm has grown since its inception in 2010 to more than 20 in-house designers, developers, and internet marketers. The Rand team specializes in responsive website design and programming, including WordPress, Magento, WooCommerce, Shopify, Zoey, 3dcart and other e-commerce platforms; SEO (search engine optimization) and Google AdWords PPC (pay-per-click) campaigns; social media marketing; and online content marketing. Rand Internet Marketing was named a Premier Google Partner in 2016, a Google Partner AllStar in 2015 and also holds an A+ rating with the Better Business Bureau. The Rand team also supports the community through its support of local non-profit organizations such as the Leukemia & Lymphoma Society, Autism Speaks, Abi's Place, The Multiple Sclerosis Foundation and more. For more information, call 888-707-7263 or request a free initial consultation online at http://randmarketing.com/request-consultation/. Apruve is revolutionizing the way businesses buy from each other. The cloud-based platform automates the burdensome and tedious tasks that go with offering net terms, freeing up the cash needed to help businesses grow. Offering a revolving line of credit is now as easy and risk free as accepting a credit card. The entire CMaaS (Credit Management as a Service) platform streamlines the process of extending credit. Apruve's open API is easily integrated to any e-Commerce or ERP system to automatically take in order data and finance all chosen orders within 24 hours. To learn more about how Apruve can grow your business, visit www.Apruve.com.